AbbVie announced that MAVIRET is now reimbursed in Alberta, Saskatchewan and the Non-Insured Health Benefits Program. MAVIRET is a once-daily, ribavirin-free treatment for adults with chronic hepatitis C virus infection across all major genotypes. In Alberta, MAVIRET is listed effective April 1, 2019, under Special Authorization on the AB Health Drug Benefit List for treatment-naive or treatment-experienced adult patients with chronic hepatitis C infection who meet all of the following criteria. Prescribed by or in consultation with a hepatologist, gastroenterologist or infectious disease specialist; AND Laboratory confirmed hepatitis C genotype 1, 2, 3, 4, 5, 6; AND Laboratory confirmed quantitative HCV RNA value within the last 6 months; AND Fibrosis stage of F0 or greater. In Saskatchewan, MAVIRET is listed effective April 1, 2019, on the Saskatchewan formulary as an Exception Drug Status product, for treatment naive and treatment experienced adult patients with chronic hepatitis C infection according to the following criteria: Laboratory confirmed hepatitis C genotype 1, 2, 3, 4, 5 or 6; AND Laboratory confirmed quantitative HCV RNA value within the last six months; AND Treatment is prescribed by a hepatologist, gastroenterologist or an infectious disease specialist or other prescriber experienced in the treatment of hepatitis C as determined by the Drug Plan. For the Non-Insured Health Benefits program, MAVIRET is listed effective April 1, 2019, under Limited Use on the NIHB Drug Benefit List for treatment-naive or treatment-experienced adult patients with chronic hepatitis C infection who meet all of the following criteria: Prescribed by or in consultation with a hepatologist, gastroenterologist or infectious disease specialist; AND Laboratory confirmed hepatitis C genotype 1, 2, 3, 5, 6; AND Laboratory confirmed quantitative HCV RNA value within the last 6 months; AND Fibrosis stage of F0 or greater.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.